Lumakras is the next test of FDA’s hardening stance
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.